Lymphatic leukaemias and some malignant lymphomas which have been treated apparently successfully with antineoplastic drugs sometimes recur in the meninges where presumably the cells have been protected from the chemotherapeutic agents by the blood-brain barrier. In some centres it has become the practice to use prophylactic cranial radiotherapy and intrathecal methotrexate to try to prevent this. This paper (Accepted 16 April 1975.) describes the neuropathological findings in 10 patients given this regime, five of whom had malignant meningitis, and in the other five it was given as prophylactic treatment. In order to eliminate changes due either to the leukaemia itself or to systemic chemotherapy, 10 control brains were examined in the same detail from patients who had leukaemia treated with antineoplastic drugs but without any intrathecal drugs or radiotherapy. PATHOLOGY Examination of the brain showed some white matter swelling but no other abnormality. The histology of the white matter showed large areas of myelin pallor mainly deep in the white matter, sparing the U fibres, the corpus callosum, and the corticospinal fibres. In the pale areas most of the oligodendrocytes had disappeared, a number of ghosts remaining (Fig. 1 ). There was a gradation of change from areas where there was a reduction in the number of oligodendrocytes to areas where nearly all the nuclei were missing although blood vessels were intact. The myelin sheaths, though pale, could be seen to be intact, and there were no fat granule cells. There was a moderate astrocytosis away from the severely damaged areas but Weil Davenport stains showed no increase of microglia. The cortex showed no significant abnormality, the blood vessels were normal and there was no thrombosis. No PATHOLOGY Examination of the brain showed white matter oedema and some areas of discolouration. Histologically, there was no leukaemic meningitis and the cortex showed no significant abnormality. There were areas of coagulative necrosis of varying size in the white matter of both cerebral and cerebellar hemispheres (Fig. 4) and also areas of localized oedema as seen in case 2. There were a large number of these foci and none were seen to be perivascular. The brain away from the lesions showed severe diffuse astrocytosis with little glial fibre formation, but the lesions themselves showed no gliosis. The lesions may have been stages in the same process. There were a few blood vessels showing fibrinoid necrosis but elsewhere they were normal. These showed similar lesions and the pathology will be considered together. There was patchy loss of oligodendrocytes leaving relatively large areas of white matter devoid of nuclei, but no dying or abnormal nuclei were seen. The most striking feature was the severe astrocytosis ( Fig. 5 ) with comparatively little fibre formation. This was somewhat variable in distribution. In case 9 it was mainly beneath the cortex, but in most of the others it could be found in varying severity throughout the central white matter of the cerebrum and cerebellum. There was sparing of the corpus callosum, the corticospinal pathway and the brain stem. Case 4 showed malignant invasion of the hypothalamus, but no malignant meningitis. Case 6 showed leukaemic meningitis with some extension in along the VirchowRobin spaces.
Case 10, who had only two doses of methotrexate The patients examined all received intrathecal methotrexate with or without cranial radiotherapy or cytosine arabinoside. The latter was given to four patients but the changes were not significantly different from the others. Since no patient received cytosine arabinoside without methotrexate, it was not possible to assess the effects of this alone. The possible synergistic effect of radiation must be considered. Freeman et al. (1973) have described a syndrome of somnolence occurring about six weeks after completion of cranial irradiation in children receiving prophylactic radiotherapy for acute lymphoblastic leukaemia. Some of their patients had intrathecal methotrexate as well, but the incidence of the syndrome was the same in the two groups. Jones (1964) has also described transient radiation myelopathy after spinal cord irradiation. Acute destruction of some oligodendroglial cells with swelling might certainly account for temporary white matter disturbance.
Cranial radiotherapy has been in use for many years for treating brain tumours and doses many times that received by these patients have been given. The severe lesions involving complete loss of oligodendrocytes in large areas are unlikely to have been missed even if the clinical picture were confused by the primary lesion. When damage has been reported it has usually been delayed, occurring many years after conclusion of the treatment. This appears to be an entirely different lesion and may have a vascular basis.
There have been a number of reports of brain damage after methotrexate injection into the CSF pathways (Wilson and Norrell, 1969; Bresnan et al., 1972; Shapiro et al., 1973; Norrell et al., 1974) . The drug has been given for brain tumours, often intraventricularly and in many cases there has been obstruction in the ventricular system. The main histological changes seen were areas of coagulative necrosis in the white matter as in case 3, although there was no ventricular obstruction in this case. If the drug is given intraventricularly it places it close to the central white matter. In case 3 the damage was severe, but it was also present in the white matter ofthe cerebellum. Rubin et al. (1968) have shown that, in dogs, tritiated methotrexate diffuses through the brain in a similar manner to inulin, and that in vitro it can enter the choroid plexus against the concentration gradient. Although the damage may be dose-dependent, what evidence there is suggests that it spreads diffusely throughout the nervous tissue even when given into the lumbar theca. In fact, if it did not do so, it would be ineffective as foci of perivascular malignancy deep in the brain are often seen post mortem. Kay et al. (1972) described seven cases of encephalopathy after intrathecal methotrexate presenting mainly as confusion, dementia, and unsteadiness with EEG changes. One brain was examined histologically and showed lesions described as infarcts, and fibrinoid necrosis of blood vessel walls. They do not say whether there were fat granule cells or myelin breakdown. These lesions may be of a similar nature to those seen in case 2, although there was no fibrinoid necrosis here.
It seems that methotrexate itself has a direct toxic effect on the oligodendrocyte. This cell does have a rather different metabolic make-up to the neurone which is unaffected. It is dependent largely on the pentose shunt for its energy and is low in Krebs cycle enzymes and cytochrome oxidase (Meyer and Meyer, 1964 ). This does not, however, explain why it should be more sensitive to folate antagonists. It is possible that the methotrexate remains bound to the cell, inhibiting further nucleic acid synthesis (Berlin, 1963) . If such a cell sustained a chromosome fracture during radiotherapy, it might not be able to repair it as the repair process requires DNAdependent RNA synthesis (Zeman, 1966) . In this way, radiotherapy might exacerbate the damage, although it would not affect significantly the normal cell.
Intrathecal methotrexate may have two possible sequelae. One is severe brain damage, possibly fatal. If this occurs after a normal single course of treatment, it must be assumed that the patient has some metabolic abnormality which makes him unduly sensitive to folate deficiency. The second probably occurs in most cases and consists of patchy oligodendroglial loss with severe consecutive astrocytosis. This has no obvious clinical expression and in the context of a fatal disease, such as leukaemia, could be considered irrelevant. However, some of these children and young adults are surviving long periods and are possibly cured, therefore any brain damage is undesirable. Four of the patients described here received cytosine arabinoside intrathecally in addition to methotrexate. There is, so far, no evidence that this drug produces additional damage, but no brain was examined which had been in contact with this drug alone. Consideration might be given to using it instead of methotrexate for a trial period. 
